261 related articles for article (PubMed ID: 18537595)
1. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.
Nawa A; Luo C; Zhang L; Ushjima Y; Ishida D; Kamakura M; Fujimoto Y; Goshima F; Kikkawa F; Nishiyama Y
Curr Gene Ther; 2008 Jun; 8(3):208-21. PubMed ID: 18537595
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
4. "Armed" oncolytic herpes simplex viruses for brain tumor therapy.
Todo T
Cell Adh Migr; 2008; 2(3):208-13. PubMed ID: 19262110
[TBL] [Abstract][Full Text] [Related]
5. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
6. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
8. Intravesical treatment of advanced urothelial bladder cancers with oncolytic HSV-1 co-regulated by differentially expressed microRNAs.
Zhang KX; Matsui Y; Lee C; Osamu O; Skinner L; Wang J; So A; Rennie PS; Jia WW
Gene Ther; 2016 May; 23(5):460-8. PubMed ID: 26905370
[TBL] [Abstract][Full Text] [Related]
9. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
Long Y; Mi Y; Li Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
[TBL] [Abstract][Full Text] [Related]
10. Targeted oncolytic herpes simplex viruses for aggressive cancers.
Wong J; Lee C; Zhang K; Rennie PS; Jia W
Curr Pharm Biotechnol; 2012 Jul; 13(9):1786-94. PubMed ID: 21740360
[TBL] [Abstract][Full Text] [Related]
11. Modification of HSV-1 to an oncolytic virus.
Nakashima H; Chiocca EA
Methods Mol Biol; 2014; 1144():117-27. PubMed ID: 24671680
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Hum Cell; 2002 Sep; 15(3):151-9. PubMed ID: 12703545
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
15. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
16. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic herpes simplex virus engineering and preparation.
Agarwalla PK; Aghi MK
Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
[TBL] [Abstract][Full Text] [Related]
18. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic HSV-1 for the treatment of brain tumours.
Markert JM; Parker JN; Buchsbaum DJ; Grizzle WE; Gillespie GY; Whitley RJ
Herpes; 2006 Nov; 13(3):66-71. PubMed ID: 17147910
[TBL] [Abstract][Full Text] [Related]
20. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
